wAMD, CSC, PCV, CCH
Conditions
Interventions
AMD group, PCV group, CSC group, CCH group and normal group:Nil
Sponsors
Eye & ENT Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Normal population: 1.The best corrected visual acuity of both eyes is 1.0, the spherical lens degree is not greater than 4.00, or not less than -6.00; 2.Comprehensive vitreoretinal examination by an experienced ophthalmologist showed no obvious abnormality; 3.No systemic vascular diseases such as hypertension or diabetes; 4.Sign the informed consent wAMD: 1.Patient was 50 years old; 2.patients had different degrees of pigment epithelial lesions in the fundus. 3.Fluorescent angiography showed obvious CNV lesions with fundus leakage. 4.Patients with new onset of AMD who have not previously received surgery or intraocular injection of PDT or anti-VEGF drugs PCV: 1.Within 5-6 minutes after ICGA imaging, the patient showed single or multiple nodular polyps or grape-like hyperfluorescence lesions, with or without related abnormal branching choroidal vascular hyperplasia; 2.Patients with primary PCV and no previous operation or intraocular injection of PDT or anti-VEGF drugs; 3.Sign informed consent and be willing to carry out relevant ophthalmic examination and use their data for research. CSC: 1.Patients with acute mesoplasma can see translucent vesicular swelling under funduscopy, and typical ink stain leakage can be seen by FFA examination; 2.Patients with primary CSC who have not previously received surgery or intraocular injection of PDT or anti-VEGF drugs; 3.Sign informed consent and be willing to carry out relevant ophthalmic examination and use their data for research. CCH: 1.The lesions of subretinal eminence can be seen under funduscopic view, with or without local omental eminence. Strong tumor fluorescence can be seen in ICGA at early stage, and clear blood vessels can be seen in the tumor, followed by rapid decrease of fluorescence. 2.Patients with primary CCH and no previous operation or intraocular injection of PDT or anti-VEGF drugs. 3.Sign informed consent and be willing to carry out relevant ophthalmic examination and use their data for research.
Exclusion criteria
Exclusion criteria: 1. Careful slit lamp and direct ophthalmoscopic examination by experienced doctors were performed to exclude diseases that seriously affect the transparency of the refractive interstitium, such as corneal optical scar, severe cataract and severe vitreous opacity, etc. 2. A history of eye trauma and eye surgery (except corneal refractive surgery) were excluded. 3. Glaucoma, retinal vein occlusion, hypertensive retinopathy, diabetic retinopathy and other fundus diseases should be excluded. 4. The BCVA of the affected eye is not less than 0.05, the spherical degree is not more than 4.00, or not less than -6.00.Patients with significant subretinal bleeding, fluid effusion, or vitreous hemorrhage that interfered with imaging were excluded. 5. Patients should be able to cooperate to complete the relevant examination, if not, they will be excluded. 6. Patients with unqualified OCTA images were excluded.The image quality of OCTA is evaluated by at least two ophthalmologists, including image sharpness and signal strength. If the image does not meet the requirements, it will be redone once. If the results still do not meet the requirements after two redoes, the image quality will be judged as failing. 7. Patients who did not sign informed consent and refused to use test results for research purposes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| diameter of choroidal vessels and choroidal thickness; | — |
Countries
China
Contacts
Public ContactMin Wang
Eye & ENT Hospital, Fudan University
Outcome results
None listed